Ratings CStone Pharmaceuticals

Equities

2616

KYG2588M1006

Market Closed - Hong Kong S.E. Other stock markets 04:08:22 2024-05-10 am EDT			5-day change	1st Jan Change
1.08 ^HKD	-6.90%		-0.92%	-52.42%

May. 06	Cstone Pharmaceuticals To Present Cancer Results at 2024 ASCO	MT
May. 02	Non-Executive Director Increases Shareholding in CStone Pharma; Shares Surge 25%	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
With regards to fundamentals, the enterprise value to sales ratio is at 0.9 for the current period. Therefore, the company is undervalued.
For several months, analysts have been revising their EPS estimates roughly upwards.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CSTONE PHARMACEUTICALS	-52.42%	176M	-
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B	B+
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B	B+
ARGENX SE	+1.28%	22.25B	B
BIONTECH SE	-13.14%	22.09B	B+
GENMAB A/S	-7.05%	18.68B	A-
WUXI APPTEC CO., LTD.	-38.36%	17.58B	A-
BEIGENE, LTD.	-10.66%	16.85B	B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B	C+
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes